Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Data Add To Strengthening Efficacy Case For Takeda Dengue Vaccine

Executive Summary

Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.

Advertisement

Related Content

Sanofi's Dengue Vaccine Health Warning Seen Hitting Product's Sales
Takeda's Dengue Vaccine Still Promising, But Could Be A Niche Market
Biological E Taps Takeda Tech For Affordable Combo Vaccines
Sun’s ‘Game Changing’ Dengue Drug May Launch In Four Years
Sanofi's Dengue Vaccine Is World's First Approved

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel